News | August 02, 2025
Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
Subscribe To Our Newsletter & Stay Updated
